Autolus Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

LONDON, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that Dr. Christian Itin, chairman and chief executive officer, will present at the 38^th annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020 at 5:00 pm Pacific Time. The company will also host one-on-one meetings with attendees.

A live audio webcast of the presentation will be available on the investor relations section of Autolus’ website at https://www.autolus.com. An archived replay will be available on the company’s website for a period of 90 days after the conference.

About Autolus Therapeutics plc

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information, go to: https://www.autolus.com.

Contacts:
Julia Wilson
JW Communications
+44 (0) 7818 430877
j.wilson@autolus.com

Susan A. Noonan
S.A. Noonan Communications
+1-212-966-3650
susan@sanoonan.com

Source: Autolus Therapeutics plc